Better long-term outcomes with low hep C viral load

March 25, 2013
Better long-term outcomes with low hep C viral load
In patients with hepatitis C virus (HCV)-related hepatocellular carcinoma, low viral load predicts better long-term surgical outcomes, regardless of the serologic eradication of HCV, according to research published in the Feb. 20 issue of the Journal of Clinical Oncology.

(HealthDay)—In patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), low HCV viral load predicts better long-term surgical outcomes, regardless of the serologic eradication of HCV, according to research published in the Feb. 20 issue of the Journal of Clinical Oncology.

Junichi Shindoh, M.D., Ph.D., of the University of Tokyo, and colleagues conducted a study involving 370 patients with HCV-related HCC to determine whether HCV viral load impacts the long-term outcomes of HCC after curative surgical resection.

The researchers found that patients with low viral load had a 23.7 percent higher five-year recurrence-free survival rate than those with a high HCV viral load (36.1 versus 12.4 percent). Low viral load was also associated with an 18.9 percent higher five-year overall survival (76.6 versus 57.7 percent). Patients with a high viral load were 87 percent more likely to develop compared with low viral load patients. The favorable results obtained in low viral load patients were not dependent on serologic eradication of HCV.

"In conclusion, a low viral load may predict lower recurrence and better survival in patients undergoing hepatic resection for HCV-related HCC irrespective of the serologic eradication of HCV," the authors write. "Postoperative antiviral therapy with individually adjusted intensity and incorporation of direct antiviral agents may warrant prospective study to characterize safety and impact on in patients undergoing surgical resection for HCV-associated HCC."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Hypoferremia predicts treatment response to IFN-α

March 1, 2012

(HealthDay) -- For patients with hepatitis C virus (HCV), hepcidin, a regulator of iron homeostasis, is induced following a single dose of pegylated interferon-α (PEG-IFNα), and may be a surrogate marker of immediate ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.